CN109803650A - 包含大麻素受体结合配体的组合物 - Google Patents

包含大麻素受体结合配体的组合物 Download PDF

Info

Publication number
CN109803650A
CN109803650A CN201780058931.9A CN201780058931A CN109803650A CN 109803650 A CN109803650 A CN 109803650A CN 201780058931 A CN201780058931 A CN 201780058931A CN 109803650 A CN109803650 A CN 109803650A
Authority
CN
China
Prior art keywords
pharmaceutical composition
thc
composition according
binding partner
receptor binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780058931.9A
Other languages
English (en)
Chinese (zh)
Inventor
伯恩哈德·金特
弗兰克·洛施尔
索尼娅·克罗斯尔
菲利普·史蒂文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaliq GmbH
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of CN109803650A publication Critical patent/CN109803650A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780058931.9A 2016-09-28 2017-09-27 包含大麻素受体结合配体的组合物 Withdrawn CN109803650A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP16191194.6 2016-09-28
EP17168172.9 2017-04-26
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
CN109803650A true CN109803650A (zh) 2019-05-24

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780058931.9A Withdrawn CN109803650A (zh) 2016-09-28 2017-09-27 包含大麻素受体结合配体的组合物

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3698785A1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
MX360469B (es) 2012-09-12 2018-11-05 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
DE202013012753U1 (de) 2012-09-12 2019-03-04 Novaliq Gmbh Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
ES2953837T3 (es) 2015-09-30 2023-11-16 Novaliq Gmbh 2-perfluorobutil pentano para administración oftálmica
CN120884568A (zh) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 半氟化化合物和其组合物
AU2017260444B2 (en) 2016-05-03 2019-05-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
EP3442480B1 (en) 2016-06-23 2019-10-02 Novaliq GmbH Topical administration method
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
MX388460B (es) 2017-04-21 2025-03-20 Dermaliq Therapeutics Inc Composiciones de yodo.
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
IL273531B2 (en) 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP3706843B1 (en) 2017-11-08 2024-06-26 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP7665519B2 (ja) * 2019-02-01 2025-04-21 アルコン インコーポレイティド 近視を治療するための化合物、組成物及び医薬組成物
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
US12576039B2 (en) 2020-05-18 2026-03-17 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US20230363441A1 (en) * 2020-09-24 2023-11-16 Nicoventures Trading Limited Formulation
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2022169788A1 (en) 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions
ES3040366T3 (en) 2021-06-22 2025-10-30 Pneuma Respiratory Inc Droplet delivery device with push ejection
WO2023064477A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
US12161795B2 (en) 2022-07-18 2024-12-10 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026047389A1 (en) * 2024-08-30 2026-03-05 Vicadia Lda Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102652022A (zh) * 2009-12-14 2012-08-29 诺瓦利克有限责任公司 治疗干眼综合征的药物组合物
CN104619314A (zh) * 2012-09-12 2015-05-13 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN104755073A (zh) * 2012-09-12 2015-07-01 诺瓦利克有限责任公司 半氟化烷烃组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
WO2010051541A2 (en) 2008-10-31 2010-05-06 The University Of Mississippi Compositions containing delta-9-thc-amino acid esters and process of preparation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
EP3071193B1 (en) 2013-11-20 2020-01-08 Panag Pharma Inc. Compositions and methods for treatment of ocular inflammation and pain
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102652022A (zh) * 2009-12-14 2012-08-29 诺瓦利克有限责任公司 治疗干眼综合征的药物组合物
CN104619314A (zh) * 2012-09-12 2015-05-13 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN104755073A (zh) * 2012-09-12 2015-07-01 诺瓦利克有限责任公司 半氟化烷烃组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DR FRANJO GROTENHERMEN: "Cannabinoids for therapeutic use: Designing systems to increase efficacy and reliability", 《AMERICAN JOURNAL OF DRUG DELIVERY》 *
DUTESCU R M ET AL: "Semifluorinated alkanes as a liquid drug carrier system for topical ocular drugdelivery", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》 *
STEVEN P. ET AL: "Semifluorinated Alkane Eye Drops for Treatment of Dry-Eye Disease - A Prospective,Multicenter, Non Interventional Study", 《JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS》 *

Also Published As

Publication number Publication date
CA3036313A1 (en) 2018-04-05
BR112019006194A2 (pt) 2019-06-18
US20190343793A1 (en) 2019-11-14
JP2019534867A (ja) 2019-12-05
AU2017333420A1 (en) 2019-04-04
EP3698785A1 (en) 2020-08-26
EP3518921B1 (en) 2021-08-11
WO2018060282A1 (en) 2018-04-05
EP3518921A1 (en) 2019-08-07
KR20190060787A (ko) 2019-06-03
MX2019003544A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
CN109803650A (zh) 包含大麻素受体结合配体的组合物
Üstündağ Okur et al. Novel ocular drug delivery systems: An update on microemulsions
Lallemand et al. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts
CA2851398C (en) Compositions for the treatment of dry eye
CN112135603B (zh) 包含奈必洛尔的药物组合物
KR20190100283A (ko) 건성 안 질환 치료용 안구 조성물
CN103501771B (zh) 用于上睑下垂的非手术治疗的组合物和方法
AU2014244154B2 (en) Microemulsion topical delivery platform
CN113518619A (zh) 用于治疗眼部新生血管形成的药物组合物
KR102663319B1 (ko) 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
UA121399C2 (uk) Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
US20200306218A1 (en) Ophthalmic composition for treating dry eye and symptoms thereof
Cruysberg et al. The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds
WO2022204111A1 (en) Composition for treating ophthalmic conditions and methods of use thereof
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40008248A (en) Compositions comprising a cannabinoid receptor binding ligand
KR20130038512A (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
HK40044057B (zh) 包含奈必洛尔的药物组合物
HK40062272A (en) Pharmaceutical composition for the treatment of ocular neovascularisation
Hingorani Preformulation Characterization And Formulation Development of Δ9-Tetrahydrocannabinol Prodrugs For Potential Treatment Of Glacuoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008248

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40008248

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190524